Sign in
WithdrawnPhase 1/2

Anti-CD19 Universal CAR-T Cells for r/r CD19+ B-ALL

Key facts

Who runs it
Kunming Hope of Health Hospital
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Withdrawn
Phase
Phase 1/2
Started
1 Oct 2022
Ended
31 Oct 2024
Type of study
Interventional
Treatments tested
  • U-CAR-T Cells (LstCAR019)
Record updated
30 November 2022
Why it stopped
The PI decides to stop.

Who can take part

Age
2 years to 75 years
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (27)Hide the full registry criteria

Who can take part

  • Male or female, aged 2-75 years
  • A definite diagnosis of relapsed/refractory B-ALL and a percentage of primitive/naive lymphocytes >5% in bone marrow at baseline (flow cytometry)
  • CD19 expression was positive in bone marrow or peripheral blood tumor cells
  • ECOG score 0-2 points
  • Expected survival time ≥3 months
  • Adequate liver, kidney, heart and lung function
  • Patients who have recovered from acute toxic effects of prior chemotherapy should be excluded from the trial at least one week apart
  • Women of childbearing age have negative blood pregnancy test before the start of the trial, and agree to take effective contraceptive measures during the trial until the last follow-up; male subjects with partners of childbearing potential agree to take effective contraceptive measures during the trial until the last follow-up
  • Voluntarily sign the informed consent

Who cannot take part

  • Presence of other concurrent active malignancy
  • Had grade III-IV heart failure or myocardial infarction, cardiac angioplasty or stenting, unstable angina pectoris, or other clinically prominent heart disease within one year prior to enrollment
  • Had undergone other clinical trials in the 4 weeks prior to participating in this trial
  • For patients contraindicated with cyclophosphamide and fludarabine chemotherapy
  • Subjects requiring systemic corticosteroid therapy (prednisone ≥5mg/ day or equivalent dose of another corticosteroid) or other immunosuppressive agents within 1 month after LstCAR019 cell reinfusion, except for adverse events
  • People with severe mental disorders
  • A history of any of the following genetic disorders, such as Fanconi anemia, Schu-Day syndrome, Gerstmann syndrome, or any other known bone marrow failure syndrome
  • A history or disease of the central nervous system(CNS), such as seizure disease, cerebrovascular ischemia/bleeding, dementia, cerebellar disease, or any autoimmune disease involving the CNS
  • Human immunodeficiency virus (HIV) seropositivity; Hepatitis B surface antigen positive or hepatitis B core antibody positive, and HBV-DNA positive; Patients with hepatitis C (HCV-RNA quantitative test results positive); Or the presence of other serious active viral or bacterial infections or uncontrolled systemic fungal infections
  • Patients with severe history of allergy or allergic constitution
  • A history of autoimmune diseases (e.g., Crohn's disease, rheumatoid arthritis, systemic lupus erythematosus) leading to end-organ damage or requiring systemic immunosuppressive/systemic disease modulating drugs within the past 2 years
  • Had or is suffering from interstitial lung disease (e.g., pneumonia, pulmonary fibrosis)
  • Any other condition that the investigator deemed inappropriate for inclusion
  • Receiving donor lymphocyte infusion within 6 weeks before enrollment
  • Acute GVHD of grade II-IV or extensive chronic GVHD
  • The presence of any indwelling catheter or drainage (e.g., percutaneous nephrostomy, indwelling catheter, bile drainage, or pleural/peritoneal/pericardial catheter), except for patients who are permitted to use dedicated central venous catheters
  • Poor compliance due to physiological, family, social, geographical and other factors, unable to cooperate with the study protocol and follow-up plan
  • Pregnant and lactating women

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This is a single-arm, single-center, open-labeled clinical study to evaluate the safety and efficacy of LstCAR019 injection for patients with relapsed/refractory(r/r) B-cell Acute Lymphoblastic Leukemia(B-ALL).

The group in the trial

  • U-CAR-T Cells (LstCAR019)Treatment being tested

    Subjects who meet the enrollment conditions will receive intravenous infusion of U-CAR-T Cells (LstCAR019) after lymphodepletion.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
An Investigator-initiated Trial to Evaluate the Efficacy and Safety of Anti-CD19 Universal CAR-T Cells in the Treatment of Relapsed/Refractory(r/r) CD19+ B-cell Acute Lymphoblastic Leukemia(B-ALL)
Record updated
30 November 2022